Inclusion Criteria:

- Subjects with biopsy-proven metastatic (soft tissue) neuroendocrine tumors.

- Subjects with a Southwest Oncology Group (SWOG) performance score of 0-2 and an
expected median survival of at least 6 months.

- The subject is able and willing to comply with study procedures and a signed and
dated informed consent is obtained.

- Subjects must be >18 years of age

Exclusion Criteria:

- Subjects who use medications that are known to interfere with MIBG uptake and is
unable to discontinue for medical reasons.

- Prior chemotherapy, radiotherapy or any investigational drugs within 60 days prior
admission into this study. Patients must have recovered from all therapy-related
toxicities

- Renal insufficiency with a serum creatinine > 2mg/dl.

- Subjects unable to lie still for the imaging studies.

- Subjects who because of their weight and body distribution do not fit into the
imaging machine.

- Subjects receiving Sandostatin LAR < 21 days prior to dosing or Sandostatin Immediate
Release (IR) < 24 hours prior to dosing.

- Female patients who are pregnant or breast feeding. Women of childbearing potential
must have a negative serum/urine pregnancy test within 48 hours prior to
administration of study treatment.